VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML by Liru Wang, Bei Jia, David F. Claxton, W Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Muhammad R. Khawaja, Jeff Sivik, Junyan Han, Raymond J. Hohl, Hong Zheng

Subjects: Get full text

Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review by Yun-zi Wang, Ji-sheng Wang, Jiang Du, Xue-li Tang, Jing-ping Xiao

Subjects: Get full text

Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma by Hanrui Zheng, Hanrui Zheng, Jiafeng Li, Feng Wen, Feng Wen, Feng Wen, Na Su, Na Su

Subjects: Get full text

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives by Markus V. Heppt, Christoffer Gebhardt, Jessica C. Hassel, Mareike Alter, Ralf Gutzmer, Ulrike Leiter, Carola Berking

Subjects: Get full text

Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events by Tongji XIE, Shouzheng WANG, Puyuan XING

Subjects: “…programmed cell death protein 1…”
Get full text

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma by Jie Mei, Jie Mei, Jie Mei, Yu-Hao Tang, Yu-Hao Tang, Yu-Hao Tang, Wei Wei, Wei Wei, Wei Wei, Ming Shi, Ming Shi, Ming Shi, Lie Zheng, Lie Zheng, Lie Zheng, Shao-Hua Li, Shao-Hua Li, Shao-Hua Li, Rong-Ping Guo, Rong-Ping Guo, Rong-Ping Guo

Subjects: Get full text

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma by Hsin-Yu Kuo, Meng-Zhi Han, Chih-Hsiang Liao, Yih-Jyh Lin, Chung-Teng Wang, Shang-Hung Chen, Ting-Tsung Chang, Po-Jun Chen, Sheng-Hsiang Lin, Chiung-Yu Chen, Chiao-Hsiung Chuang, I-Chin Wu, Juei-Seng Wu, Tzu-Chun Hong, Ming-Tsung Hsieh, Yang-Cheng Lee, Hung-Tsung Wu, Hong-Ming Tsai

Subjects: Get full text

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases by Vishakha Singh, Amit Khurana, Amit Khurana, Amit Khurana, Amit Khurana, Prince Allawadhi, Anil Kumar Banothu, Kala Kumar Bharani, Ralf Weiskirchen

Subjects: “…programmed cell death protein 1…”
Get full text

Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients by Yuxin Zhou, Wenjing Mu, Chen Wang, Zipeng Zhuo, Yu Xin, Hongxu Li, Changsong Wang

Subjects: Get full text

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations by Jiqiao Yang, Jiqiao Yang, Jiqiao Yang, Xiujing He, Xiujing He, Qing Lv, Qing Lv, Jing Jing, Hubing Shi, Hubing Shi

Subjects: “…programmed cell death protein 1…”
Get full text

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer by Zhong-Yi Dong, Jia-Tao Zhang, Si-Yang Liu, Jian Su, Chao Zhang, Zhi Xie, Qing Zhou, Hai-Yan Tu, Chong-Rui Xu, Li-Xu Yan, Yu-Fa Li, Wen-Zhao Zhong, Yi-Long Wu

Subjects: Get full text

Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma by Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, Zheng L, Chen MS, Shi M, Wei W, Guo RP

Subjects: Get full text

Correlation Between Tumor-Associated Macrophage and Immune Checkpoint Molecule Expression and Its Prognostic Significance in Cutaneous Melanoma by Young Jae Kim, Chong Hyun Won, Mi Woo Lee, Jee Ho Choi, Sung Eun Chang, Woo Jin Lee

Subjects: Get full text

Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review by Si-Hong Lin, Ao Zhang, Lu-Zhen Li, Liang-Chen Zhao, Le-Xia Wu, Can-Tu Fang

Subjects: Get full text

Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice by Haifeng Huang, Hua Zhu, Quan Xie, Xiaobin Tian, Xianteng Yang, Fan Feng, Qiyu Jiang, Xinan Sheng, Zhi Yang

Subjects: Get full text

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity by Paulina Niedźwiedzka-Rystwej, Adam Majchrzak, Bogusz Aksak-Wąs, Karol Serwin, Zenon Czajkowski, Ewelina Grywalska, Izabela Korona-Głowniak, Jacek Roliński, Miłosz Parczewski

Subjects: Get full text

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies by Wenwen Yang, Caining Lei, Shaoming Song, Wutang Jing, Chuanwei Jin, Shiyi Gong, Hongwei Tian, Tiankang Guo

Subjects: Get full text

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review by Cunli Yin, Bin Hu, Xi Yang, Lingna Kou, Bo Tian, Chenghao Wang, Siru Li, Bin Liu, Jun Ge

Subjects: Get full text

A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab by Annie A. Guedikian, Megan E. Randall, Anita Sharko, William T. Leslie

Subjects: Get full text

Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepato... by Chao Chen, Li An, Ying Cheng, Xianwen Luo, Zixiong Li, Xiufeng Liu

Subjects: Get full text